Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Abstract | OBJECTIVES: BACKGROUND: METHODS: A total of 56 impaired glucose tolerant or diabetic patients with carotid atherosclerosis underwent a complete history, determinations of blood chemistries, anthropometric variables, and FDG-PET. They were randomly assigned to receive either pioglitazone (15 to 30 mg) or glimepiride (0.5 to 4.0 mg) for 4 months with titration to optimal dosage. Effects of the drugs on atherosclerotic plaque inflammation were evaluated by FDG-PET at study completion. Plaque inflammation was measured by blood-normalized standardized uptake value, known as a target-to-background ratio. RESULTS: CONCLUSIONS:
|
Authors | Minori Mizoguchi, Nobuhiro Tahara, Atsuko Tahara, Yoshikazu Nitta, Norihiro Kodama, Toyoharu Oba, Kazutoshi Mawatari, Hideo Yasukawa, Hayato Kaida, Masatoshi Ishibashi, Naofumi Hayabuchi, Haruhito Harada, Hisao Ikeda, Sho-Ichi Yamagishi, Tsutomu Imaizumi |
Journal | JACC. Cardiovascular imaging
(JACC Cardiovasc Imaging)
Vol. 4
Issue 10
Pg. 1110-8
(Oct 2011)
ISSN: 1876-7591 [Electronic] United States |
PMID | 21999871
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Biomarkers
- Blood Glucose
- Cholesterol, HDL
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Radiopharmaceuticals
- Sulfonylurea Compounds
- Thiazolidinediones
- hemoglobin A1c protein, human
- Fluorodeoxyglucose F18
- glimepiride
- C-Reactive Protein
- Pioglitazone
|
Topics |
- Aged
- Anti-Inflammatory Agents
(therapeutic use)
- Aortic Diseases
(diagnostic imaging, drug therapy, etiology)
- Aortography
- Biomarkers
(blood)
- Blood Glucose
(drug effects, metabolism)
- C-Reactive Protein
(metabolism)
- Carotid Artery Diseases
(diagnostic imaging, drug therapy, etiology)
- Cholesterol, HDL
(blood)
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy)
- Diabetic Angiopathies
(diagnostic imaging, drug therapy, etiology)
- Female
- Fluorodeoxyglucose F18
- Glucose Intolerance
(blood, complications, drug therapy)
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Inflammation
(diagnostic imaging, drug therapy, etiology)
- Japan
- Male
- Middle Aged
- Multimodal Imaging
- Pioglitazone
- Positron-Emission Tomography
- Predictive Value of Tests
- Prospective Studies
- Radiopharmaceuticals
- Regression Analysis
- Sulfonylurea Compounds
(therapeutic use)
- Thiazolidinediones
(therapeutic use)
- Time Factors
- Tomography, X-Ray Computed
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|